Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opioid Approval Standards Could Change Under New US FDA Plan

Executive Summary

The Overdose Prevention Framework includes considering whether FDA should require new opioids show superior safety compared to existing products.

You may also be interested in...



‘Opioids’ Is Missing From The US FDA’s Overdose Prevention Framework Title On Purpose

Unlike prior plans, the FDA’s new substance abuse framework is intended to deal with stimulant and benzodiazepine use disorders, in addition to opioid abuse.

New Opioid Approval Standard Intended To Drive Development Into Other Therapeutics

US FDA explored whether existing law allowed for the higher standard, but determined new authority granted by Congress was necessary.

FDA Guidance On Substance Use Disorder Supports Medical Device Innovation

In a 30 August guidance from the US FDA, the agency proposed support and guidance for medical device innovation to treat substance use disorder.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS146931

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel